HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,207,311 | +1.7% | 57,783 | -4.0% | 0.02% | +4.2% |
| Q2 2023 | $2,170,976 | +1.4% | 60,188 | +7.4% | 0.02% | 0.0% |
| Q1 2023 | $2,140,700 | -52.3% | 56,054 | -28.9% | 0.02% | -52.9% |
| Q4 2022 | $4,488,000 | +47.6% | 78,875 | +2.5% | 0.05% | +37.8% |
| Q3 2022 | $3,040,000 | +29.4% | 76,918 | +43.7% | 0.04% | +32.1% |
| Q2 2022 | $2,349,000 | -24.2% | 53,525 | -31.0% | 0.03% | -15.2% |
| Q1 2022 | $3,099,000 | +10.8% | 77,583 | +11.5% | 0.03% | +17.9% |
| Q4 2021 | $2,797,000 | +12.1% | 69,569 | +13.3% | 0.03% | +7.7% |
| Q3 2021 | $2,495,000 | +7.4% | 61,400 | +19.9% | 0.03% | +13.0% |
| Q2 2021 | $2,324,000 | +13.0% | 51,219 | +4.1% | 0.02% | 0.0% |
| Q1 2021 | $2,056,000 | -5.3% | 49,218 | -3.5% | 0.02% | -8.0% |
| Q4 2020 | $2,172,000 | +39.7% | 51,021 | -13.9% | 0.02% | +19.0% |
| Q3 2020 | $1,555,000 | +15.2% | 59,260 | +17.7% | 0.02% | +5.0% |
| Q2 2020 | $1,350,000 | +20.1% | 50,347 | -19.6% | 0.02% | +25.0% |
| Q1 2020 | $1,124,000 | +3.8% | 62,618 | +3.3% | 0.02% | +6.7% |
| Q4 2019 | $1,083,000 | +20.6% | 60,597 | +3.8% | 0.02% | +15.4% |
| Q3 2019 | $898,000 | -6.9% | 58,403 | +4.2% | 0.01% | -7.1% |
| Q2 2019 | $965,000 | +11.9% | 56,028 | +4.6% | 0.01% | 0.0% |
| Q1 2019 | $862,000 | +22.8% | 53,546 | +11.7% | 0.01% | +7.7% |
| Q4 2018 | $702,000 | +11.1% | 47,926 | +37.1% | 0.01% | +30.0% |
| Q3 2018 | $632,000 | +12.9% | 34,954 | +5.3% | 0.01% | +11.1% |
| Q2 2018 | $560,000 | -28.8% | 33,192 | -17.5% | 0.01% | -30.8% |
| Q1 2018 | $787,000 | +1.8% | 40,219 | +5.6% | 0.01% | 0.0% |
| Q4 2017 | $773,000 | +16.4% | 38,098 | -0.8% | 0.01% | 0.0% |
| Q3 2017 | $664,000 | +43.4% | 38,403 | +6.2% | 0.01% | +44.4% |
| Q2 2017 | $463,000 | +38.6% | 36,156 | +41.5% | 0.01% | +28.6% |
| Q1 2017 | $334,000 | +74.9% | 25,560 | +31.2% | 0.01% | +75.0% |
| Q4 2016 | $191,000 | -29.8% | 19,485 | -13.6% | 0.00% | -33.3% |
| Q3 2016 | $272,000 | – | 22,558 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |